In recent weeks, major Wall Street firms have updated their outlooks on CVS following equity moves earlier this month. Bank of America lowered its price target from 100 to 95 while retaining a buy rating, citing attractive valuation relative to peers. Sanford C. Bernstein reaffirmed a market perform stance with a 91 target, and TD Cowen and Evercore ISI both raised targets to 105 and 95 respectively, maintaining buy and outperform recommendations. Overall, twenty analysts recommend buy and four hold, supporting a moderate buy consensus despite heightened volatility.

Investor concerns intensified when the Centers for Medicare & Medicaid Services proposed a negligible 0.09% increase to Advantage plan rates for 2027, well below the 4–6% uplift anticipated by the market. This policy development directly pressures CVS’s pharmacy benefit management and insurance revenues, contributing to a broader sell-off in managed-care names. Although CVS’s stock decline was smaller than some peers, the rate outcome underscores regulatory risk and may temper insurance segment growth forecasts for the next fiscal year.

CVS reported revenue of 102.9 billion for its most recent quarter, surpassing consensus by more than four billion on year-over-year growth of 7.8%. Adjusted EPS came in at 1.60, topping estimates by 0.24. Management reiterated full-year 2025 earnings guidance in the range of 6.55 to 6.65 per share, underpinned by robust retail pharmacy performance and improving clinic utilization. The board declared a quarterly dividend of 0.665, translating to a 3.7% yield on a full-year basis, reflecting confidence in free cash flow generation and capital return priorities.